GILDGilead SciencesSigning up patients
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple Negative Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,514 (planned)
- Started
- Dec 12, 2022
- Main results expected
- Jun 2027
- Fully finished
- Aug 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Invasive Disease-free Survival (iDFS)
Measured over: Up to 60 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05633654 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC